Updated: Even with no primary endpoint data, TauRx still eyes Alzheimer’s filing after PhIII update

De­spite its in­abil­i­ty to con­duct a Phase III pri­ma­ry analy­sis, Tau­Rx is plan­ning reg­u­la­to­ry fil­ings for its tau ag­gre­ga­tion in­hibitor in Alzheimer’s dis­ease af­ter re­port­ing up­dat­ed re­sults.

In No­vem­ber 2022, Tau­Rx pre­sent­ed topline da­ta from a sub­set of pa­tients in the LU­CID­I­TY tri­al of hy­dromethylth­io­n­ine me­sy­late (HMTM) who had mild cog­ni­tive im­pair­ment. The com­pound used as a place­bo, methylth­ion­ini­um chlo­ride, had led to un­ex­pect­ed­ly high and clin­i­cal­ly ef­fec­tive lev­els of the ac­tive in­gre­di­ent in the blood.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.